Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Ever since monetizing its stake in multiple sclerosis drug Tysabri, Elan Pharmaceuticals has been at the center of attention. It is seemingly reinventing its business on the fly by making a flurry of deals in the past few days while at the same time being doggedly pursued by Royalty Pharma.
In this video, health-care analyst David Williamson discusses Elan's recent wheeling and dealing and whether it is in the best interests of investors.
Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.